Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Feb

Today In Oncology

Opening Session Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer

Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

Microplastics Found in 90 Percent of Prostate Cancer Samples

Proximity to Nuclear Power Plants and Cancer Risk